Ignite Creation Date:
2024-05-05 @ 11:20 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00001628
Status:
COMPLETED
Last Update Posted:
2008-03-04
First Post:
1999-11-03
Brief Title:
The Role of Angiotensin Type I Receptor in the Regulation of Human Peripheral Vascular Function
Sponsor:
National Heart Lung and Blood Institute NHLBI
Organization:
National Institutes of Health Clinical Center CC
Study Overview
Official Title:
The Role of Angiotensin Type I Receptor in the Regulation of Human Peripheral Vascular Function
Status:
COMPLETED
Status Verified Date:
1999-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The renin angiotensin system RAS plays an important physiological and pathophysiological role in the control of blood pressure and plasma volume Inhibition of the RAS is useful in the treatment of hypertension cardiac failure and in some patients with myocardial infarction Several recent clinical trials with angiotensin converting enzyme inhibitors ACEI have shown that they also reduce the incidence of myocardial infarction but the mechanisms underlying this anti-ischemic effect are poorly understood ACEI reduce angiotensin II synthesis and prevent bradykinin degradation Results from ongoing studies in the Cardiology Branch Protocol 95-H-0099 designed to investigate the link between ACEI and the vascular endothelium indicate that ACEI improve peripheral endothelial function an effect that is partially mediated by bradykinin The current protocol is designed to investigate whether the beneficial effects of ACEI on peripheral endothelial function are also due to inhibition of angiotensin II The recent development of selective angiotensin II type 1 AT1 receptor antagonists allows us to specifically examine the effects of angiotensin II on vasomotor activity
Detailed Description:
The renin angiotensin system RAS plays an important physiological and pathophysiological role in the control of blood pressure and plasma volume Inhibition of the RAS is useful in the treatment of hypertension cardiac failure and in some patients with myocardial infarction Several recent clinical trials with angiotensin converting enzyme inhibitors ACEI have shown that they also reduce the incidence of myocardial infarction but the mechanisms underlying this anti-ischemic effect are poorly understood ACEI reduce angiotensin II synthesis and prevent bradykinin degradation Results from ongoing studies in the Cardiology Branch Protocol 95-H-0099 designed to investigate the link between ACEI and the vascular endothelium indicate that ACEI improve peripheral endothelial function an effect that is partially mediated by bradykinin The current protocol is designed to investigate whether the beneficial effects of ACEI on peripheral endothelial function are also due to inhibition of angiotensin II The recent development of selective angiotensin II type 1 AT1 receptor antagonists allows us to specifically examine the effects of angiotensin II on vasomotor activity
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 97-H-0140 | None | None | None |